ReviewJournal of diabetes investigation2020
Sodium-glucose cotransporters: Functional properties and pharmaceutical potential.
Review in Journal of diabetes investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed.
- Loss of Intestinal MSTN Promotes GLP-1 Secretion Through SGLT1 Palmitoylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.Clinical pharmacology and therapeutics · 2026Article
- Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats.Journal of veterinary pharmacology and therapeutics · 2026Article
- Hypothalamic POMC neurons regulate intestinal glucose absorption via a gut-brain circuit.Nature communications · 2026Article
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- Vasculoprotective Effects of Sodium-Glucose Co-Transporter Inhibitors in Non-Diabetic Experimental Settings: A Narrative Review.International journal of molecular sciences · 2026Review
- Advances in Intestinal Glucose Absorption Regulation for Ruminant Energy Efficiency Improvement.Animals : an open access journal from MDPI · 2026Review
- Alternative methods for pharmacological research on the action mechanisms of natural products used in the treatment of type 2 diabetes: a systematic review.Frontiers in pharmacology · 2026Review
- Sirtuin 1 is a key molecular link between cellular senescence and heart failure.Frontiers in molecular medicine · 2026Review
- CW ESR spectroscopy and protein spin labeling in membrane biology.Physical biology · 2025Review
- Synteny - a high throughput web tool to streamline causal gene prioritisation and provide insight into protein function.Scientific reports · 2025Article
- Late-Night Feeding, Sleep Disturbance, and Nocturnal Congestion Mediated by Hyperglycemia, Renal Sodium Retention, and Cortisol: A Narrative Review.Clocks & sleep · 2025Review
- Influence of Certain Natural Bioactive Compounds on Glycemic Control: A Narrative Review.Nutrients · 2025Review
- SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?Life (Basel, Switzerland) · 2025Review
- HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment.Acta diabetologica · 2025Article
- High-Fructose-Induced Salt-Sensitive Hypertension: The Potential Benefit of SGLT4 or SGLT5 Modulation.Nutrients · 2025Review
- SGLT2 Inhibitors: From Structure-Effect Relationship to Pharmacological Response.International journal of molecular sciences · 2025Review
- The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?Cardiovascular diabetology · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucose is the most abundant monosaccharide, and an essential source of energy for most living cells. Glucose transport across the cell membrane is mediated by two types of transporters: facilitative glucose transporters (gene name: solute carrier 2A) and sodium-glucose cotransporters (SGLTs; gene name: solute carrier 5A). Each transporter has its own substrate specificity, distribution, and regulatory mechanisms. Recently, SGLT1 and SGLT2 have attracted much attention as therapeutic targets for various diseases. This review addresses the basal and functional properties of glucose transporters and SGLTs, and describes the pharmaceutical potential of SGLT1 and SGLT2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.